Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY24 results · Oct–Dec 2023
Solara Active Pharma Sciences reported revenue from operations of ₹248.73 crore (down 37.0% from Q3 FY23) and net loss of ₹275.34 crore for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 248.73 | 394.75 | −37.0% | 425.24 | −41.5% |
| Other income | 0.45 | 7.17 | −93.7% | 1.18 | −61.9% |
| Total income | 249.18 | 401.92 | −38.0% | 426.42 | −41.6% |
| Profit before tax | (275.34) | 0.55 | Turned loss | (17.06) | Loss widened |
| Net profit for the period | (275.34) | 0.43 | Turned loss | (17.06) | Loss widened |
| EPS, basic (₹) | (76.49) | 0.12 | Turned loss | (4.77) | Loss widened |
| Net margin (%) | -110.7 | 0.1 | -4.0 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 248.73 | 394.75 | −37.0% | 425.24 | −41.5% |
| Other income | 0.44 | 6.77 | −93.5% | 1.23 | −64.2% |
| Total income | 249.17 | 401.52 | −37.9% | 426.47 | −41.6% |
| Profit before tax | (275.33) | 0.53 | Turned loss | (15.26) | Loss widened |
| Net profit for the period | (275.33) | 0.42 | Turned loss | (15.26) | Loss widened |
| EPS, basic (₹) | (76.49) | 0.12 | Turned loss | (4.24) | Loss widened |
| Net margin (%) | -110.7 | 0.1 | -3.6 |
Consolidated
- Filed with BSE
- 26 Feb 2024, 17:56 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Feb 2024, 17:56 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE